Eleven drugmakers have allocated a combined $2 billion for gene therapy manufacturing since 2018, Reuters reports.
Pfizer and Novartis, according to the report, are leading the charge with $600 million and $500 million investments respectively.
“There’s so little capacity and capability at contract manufacturers for the novel gene therapy processes being developed by companies,” AveXis President David Lennon told Reuters. “We need internal manufacturing capabilities in the long term.”
To read the full report, click here.
